Mga Batayang Estadistika
| CIK | 1658551 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Amylyx Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 7, 2025 |
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results • Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide in PBH expected in 2025, with topline data anticipated in first half of 2026 • Cash, cash equivalents, and marketable securities of $180.8 million as of June 30, 2025; cash runway expected through the end of 2026 • Management to host conferen |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41199 Amylyx Pharmaceuticals, Inc. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 8, 2025 |
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results • Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA breakthrough therapy designation, underway in post-bariatric hypoglycemia (PBH); completion of recruitment expected in 2025, with topline data anticipated in first half of 2026 • Data through Week 48 from the o |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41199 Amylyx Pharmaceuticals, Inc. |
|
| May 8, 2025 |
Exhibit 10.1 Performance-Based RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE AMYLYX PHARMACEUTICALS, INC. 2022 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Expiration Date: Pursuant to the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan, as amended through the date hereof (the “Plan”), Amylyx Pharmaceuticals, |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 24, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 24, 2025 |
CORRESP VIA EDGAR March 24, 2025 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N. |
|
| March 4, 2025 |
Form of Employment Agreement, between the Registrant and Camille Bedrosian. EX-10.11 2 amlx-ex1011.htm EX-10.11 Exhibit 10.11 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Camille Bedrosian, M.D., 25 Moncada Way, San Rafael, CA, 94901 (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company beginnin |
|
| March 4, 2025 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Amylyx Pharmaceuticals, Inc. |
|
| March 4, 2025 |
As filed with the Securities and Exchange Commission on March 4, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on March 4, 2025 Registration No. |
|
| March 4, 2025 |
List of Subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES Amylyx Pharmaceuticals, Inc. had international subsidiaries shown below as of March 4, 2025. Amylyx Pharmaceuticals, Inc. is not a subsidiary of any other entity. Subsidiary Jurisdiction of Incorporation Amylyx Pharmaceuticals Canada Inc. Canada Amylyx Pharmaceuticals EMEA B.V. Netherlands Amylyx Pharmaceuticals Distribution Ltd. Ireland Amylyx Pharmaceuticals Germany Gmb |
|
| March 4, 2025 |
Power of Attorney (included on the signature page of this Registration Statement) Table of Contents As filed with the Securities and Exchange Commission on March 4, 2025 Registration No. |
|
| March 4, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Amylyx Pharmaceuticals, Inc. |
|
| March 4, 2025 |
EX-4.3 Exhibit 4.3 AMYLYX PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Tru |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 4, 2025 |
Exhibit 97.1 AMYLYX PHARMACEUTICALS, INC. COMPENSATION RECOVERY POLICY Adopted October 29, 2024 Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from current and |
|
| March 4, 2025 |
As filed with the Securities and Exchange Commission on March 4, 2025 As filed with the Securities and Exchange Commission on March 4, 2025 Registration No. |
|
| March 4, 2025 |
Form of Subordinated Debt Indenture EX-4.4 Exhibit 4.4 AMYLYX PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities a |
|
| March 4, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Amylyx Pharmaceuticals, Inc. |
|
| March 4, 2025 |
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results • Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist, in post-bariatric hypoglycemia underway; completion of recruitment expected in 2025, with topline data anticipated in first half of 2026 • Completed a public offering of common stock with net proceeds of |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41199 Amylyx Pharmace |
|
| March 4, 2025 |
Amylyx Pharmaceuticals, Inc. Insider Trading Policy. Exhibit 19.1 AMYLYX PHARMACEUTICALS, INC. AMENDED AND RESTATED STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND DISCLOSURE This memorandum sets forth the policy of Amylyx Pharmaceuticals, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Amended and Restated Insid |
|
| January 14, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| January 10, 2025 |
Underwriting Agreement, dated January 10, 2025 EX-1.1 Exhibit 1.1 Amylyx Pharmaceuticals, Inc. Common Stock Underwriting Agreement January 10, 2025 Leerink Partners LLC As representative (the “Representative”) of the several Underwriters named in Schedule I hereto, c/o Leerink Partners LLC 53 State Street, 40th Floor Boston, MA 02109 Ladies and Gentlemen: Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject t |
|
| January 10, 2025 |
17,142,857 Shares of common stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-270505 Prospectus Supplement (To prospectus dated March 13, 2023) 17,142,857 Shares of common stock We are offering 17,142,857 shares of our common stock, par value $0.0001 per share. Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol “AMLX.” On January 8, 2025, the closing price of our |
|
| January 10, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Amylyx Pharmaceuticals, Inc. |
|
| January 10, 2025 |
Sole Bookrunning Manager Leerink Partners Prospectus Supplement dated , 2025 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-270505 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 AMYLYX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or other jurisdiction of incorporation) (Comm |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 AMYLYX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or other jurisdiction of incorporation) (Com |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 7, 2024 |
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results • On track to initiate a Phase 3 program for Company’s lead asset avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations, in post-bariatric hypoglycemia (PBH) in the first quarter of 2025 • Reported positive topline data from Phase 2 HELIOS clinical trial of AMX0035 in Wolfra |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41199 Amylyx Pharmaceuticals, Inc. |
|
| October 25, 2024 |
EX-99.1 2 d875784dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: October 25, 20 |
|
| October 25, 2024 |
AMLX / Amylyx Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G 1 d875784dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03237H101 (CUSIP Number) October 18, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| October 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 AMYLYX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or other jurisdiction of incorporation) (Comm |
|
| August 26, 2024 |
AMLX / Amylyx Pharmaceuticals, Inc. / TCG Crossover GP II, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03237H101 (CUSIP Number) August 14, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to des |
|
| August 26, 2024 |
EX-99.1 2 d866005dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 8, 2024 |
Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results • Expanded pipeline with avexitide, a Phase 3-ready GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations; Phase 3 program initiation in post-bariatric hypoglycemia (PBH) on track for Q1 2025 • Company expects to present updated data from its Phase 2 HELIOS trial of AMX0035 in Wolfram s |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41199 Amylyx Pharmaceuticals, Inc. |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 21, 2024 |
Exhibit 10.1 Execution Version ASSET PURCHASE AGREEMENT by and between Amylyx Pharmaceuticals, Inc., or a wholly owned subsidiary thereof, as Purchaser, and EIGER BIOPHARMACEUTICALS, INC., as Seller Dated as of June 21, 2024 Table of Contents Page ARTICLE 1. DEFINED TERMS 1 1.1 Defined Terms 1 1.2 Other Definitional and Interpretive Matters 11 ARTICLE 2. THE PURCHASE AND SALE; CLOSING 13 2.1 Purch |
|
| June 21, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 9, 2024 |
Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results ˗ Company plans to engage with FDA based on interim data from the Phase 2 HELIOS clinical trial demonstrating improvements in pancreatic function, glycemic control, and vision in participants with Wolfram syndrome treated with AMX0035; topline data from all 12 participants at Week 24 anticipated in fall of 2024 ˗ Inte |
|
| May 9, 2024 |
Exhibit 10.1 AMYLYX PHARMACEUTICALS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of Amylyx Pharmaceuticals, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not e |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41199 Amylyx Pharmaceuticals, Inc. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 24, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 AMYLYX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or other jurisdiction of incorporation) (Commis |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 AMYLYX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or other jurisdiction of incorporation) (Commiss |
|
| April 4, 2024 |
Exhibit 99.1 Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy - Based on topline results from the Phase 3 PHOENIX trial of AMX0035 in ALS, Amylyx has started a process with the FDA and Health Canada of voluntarily discontinuing the marketing authorizations for RELY |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 AMYLYX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or other jurisdiction of incorporation) (Commis |
|
| March 11, 2024 |
AMLX / Amylyx Pharmaceuticals, Inc. / Panacea Innovation Ltd - SC 13G Passive Investment SC 13G 1 d745577dsc13g.htm SC 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 pe |
|
| March 11, 2024 |
EX-99 2 d745577dex99.htm EX-99 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the i |
|
| March 8, 2024 |
EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS - PHOENIX Study Did Not Meet Prespecified Primary or Secondary Endpoints - Data From 664-Participant Study Reinforce That AMX0035 is Generally Safe and Well-Tolerated - Within the Next Eight Weeks, Amylyx Will Continue to Engage With Regulatory Authorities and the ALS Commun |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 AMYLYX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or other jurisdiction of incorporation) (Commiss |
|
| February 22, 2024 |
Exhibit 97.1 AMYLYX PHARMACEUTICALS, INC. COMPENSATION RECOVERY POLICY Adopted October 2, 2023 Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from current and f |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41199 Amylyx Pharmace |
|
| February 22, 2024 |
As filed with the Securities and Exchange Commission on February 22, 2024 As filed with the Securities and Exchange Commission on February 22, 2024 Registration No. |
|
| February 22, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 22, 2024 |
Separation Agreement between Registrant and Margaret Olinger dated December 31, 2023. Exhibit 10.17 SEPARATION AND RELEASE AGREEMENT This SEPARATIONAND RELEASE AGREEMENT (the “Agreement”) is entered into by and among Margaret Olinger, M.B.A. (the “Executive”), and Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”). This Agreement is entered into effective as of December 31, 2023. The Executive and the Company are hereinafter collectively referred to as the “Partie |
|
| February 22, 2024 |
List of Subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES Amylyx Pharmaceuticals, Inc. had international subsidiaries shown below as of February 22, 2024. Amylyx Pharmaceuticals, Inc. is not a subsidiary of any other entity. Subsidiary Jurisdiction of Incorporation Amylyx Pharmaceuticals Canada Inc. Canada Amylyx Pharmaceuticals EMEA B.V. Netherlands Amylyx Pharmaceuticals Distribution Ltd. Ireland Amylyx Pharmaceuticals Germany |
|
| February 22, 2024 |
Exhibit 10.13 2nd AMENDMENT TO EMPLOYMENT AGREEMENT This 2nd Amendment to Employment Agreement (“Amendment”) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Patrick Yeramian, M.D. (“Executive”) and is effective as of November 27, 2023 (the “Effective Date”). WHEREAS, the Company and Executive are parties to that certain Employment Agreement, effective Janua |
|
| February 22, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Amylyx Pharmaceuticals, Inc. |
|
| February 22, 2024 |
Form of Employment Agreement, between the Registrant and Camille Bedrosian. Exhibit 10.15 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Camille Bedrosian, M.D., 25 Moncada Way, San Rafael, CA, 94901 (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company beginning on November 27, 2023 (the “Effecti |
|
| February 22, 2024 |
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results • Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter • Delivered $49.3 million in net income for the full year 2023, including $4.7 million in the fourth quarter, and ended the year with cash, cash equivalents and short-term investments |
|
| February 14, 2024 |
EX-99.1 2 d691263dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 14, 2024 |
AMLX / Amylyx Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d691263dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03237H 10 1 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stat |
|
| February 14, 2024 |
AMLX / Amylyx Pharmaceuticals, Inc. / VIKING GLOBAL INVESTORS LP Passive Investment SC 13G/A 1 sayw2402140813ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 3) Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title |
|
| February 14, 2024 |
SC 13G/A 1 p24-0670sc13ga.htm AMYLYX PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03237H101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this |
|
| February 13, 2024 |
AMLX / Amylyx Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0285-amylyxpharmaceuticals.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Amylyx Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 03237H101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box |
|
| December 19, 2023 |
December 19, 2023 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attn: Ms. |
|
| December 11, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p23-2949exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a |
|
| December 11, 2023 |
SC 13G 1 p23-2949sc13g.htm AMYLYX PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03237H101 (CUSIP Number) November 29, 2023 (Date of Event Which Requires Filing of this Statem |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or other jurisdiction of incorporation) (Comm |
|
| November 9, 2023 |
Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results ˗ Third quarter 2023 product revenue of $102.7 million; bringing total product revenue to $272.3 million in the first three full quarters of U.S. launch ˗ Strong financial position supported by $20.9 million of net income during the third quarter of 2023 and cash, cash equivalents and short-term investments of $355.0 |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41199 Amylyx Pharmaceuticals, Inc. |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 4, 2023 |
EX-99.1 CUSIP No. 03237H101 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party. Dated: October 4 |
|
| October 4, 2023 |
TRANSACTIONS IN COMMON STOCK EFFECTED SINCE THE FILING OF AMENDMENT NO. 3 TO THE INITIAL STATEMENT EX-99.2 CUSIP No. 03237H101 EXHIBIT 99.2 TRANSACTIONS IN COMMON STOCK EFFECTED SINCE THE FILING OF AMENDMENT NO. 3 TO THE INITIAL STATEMENT The following table sets forth all transactions by the Reporting Persons with respect to the Common Stock effected since the filing of Amendment No. 3 to the Initial Statement, through September 25, 2023. Date of transaction Entity making sale Average price Nu |
|
| October 4, 2023 |
SC 13D/A CUSIP No. 03237H101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03237H101 (CUSIP Number) Morningside Venture Investments Limited C/O THC Management Services S.A.M., 2nd F |
|
| August 17, 2023 |
SC 13D/A CUSIP No. 03237H101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03237H101 (CUSIP Number) Morningside Venture Investments Limited C/O THC Management Services S.A.M., 2nd F |
|
| August 17, 2023 |
EX-99.1 2 d528863dex991.htm EX-99.1 EXHIBIT 99.1 CUSIP No. 03237H101 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each |
|
| August 10, 2023 |
Form of Non-Qualified Stock Option Agreement for Company Employees under the 2023 Inducement Plan. EX-99.3 Exhibit 99.3 NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES UNDER THE AMYLYX PHARMACEUTICALS, INC. 2023 INDUCEMENT PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ [FMV on Grant Date] Grant Date: Expiration Date: [No more than 10 years] Pursuant to the Amylyx Pharmaceuticals, Inc. 2023 Inducement Plan, as amended through the date hereof (the “Plan |
|
| August 10, 2023 |
Amylyx Pharmaceuticals, Inc. 2023 Inducement Plan. EX-99.1 Exhibit 99.1 AMYLYX PHARMACEUTICALS, INC. 2023 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Amylyx Pharmaceuticals, Inc. 2023 Inducement Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to enable Amylyx Pharmaceuticals, Inc. (the “Company”) to grant equity awards to induce highly-qualified prospective officers an |
|
| August 10, 2023 |
Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. To: AMYLYX PHARMACEUTICALS, INC. 43 Thorndike Street Cambridge, MA 02141 Attention: Joshua Cohen (Co-CEO) |
|
| August 10, 2023 |
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results ˗ Second quarter 2023 product revenue of $98.2 million; demand and insurance coverage for RELYVRIO® in U.S. and ALBRIOZA™ in Canada continued to grow ˗ Strong financial position supported by $22.1 million of net income during the second quarter of 2023 and cash, cash equivalents and short-term investments of $357.3 m |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41199 Amylyx Pharmaceuticals, Inc. |
|
| August 10, 2023 |
Form of Restricted Stock Unit Award under the 2023 Inducement Plan. EX-99.2 Exhibit 99.2 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE AMYLYX PHARMACEUTICALS, INC. 2023 INDUCEMENT PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the Amylyx Pharmaceuticals, Inc. 2023 Inducement Plan, as amended through the date hereof (the “Plan”), Amylyx Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number o |
|
| August 10, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Amylyx Pharmaceuticals, Inc. |
|
| August 10, 2023 |
As filed with the Securities and Exchange Commission on August 10, 2023 S-8 As filed with the Securities and Exchange Commission on August 10, 2023 Registration No. |
|
| July 26, 2023 |
EX-99.1 Exhibit 99.1 Progressive Supranuclear Palsy (PSP) Investor and Analyst Conference Call July 26, 2023 On Today’s Call • Welcome Lindsey Allen, Head, Investor Relations and Communications, Amylyx • Opening Remarks Josh Cohen and Justin Klee, Co-CEOs, Amylyx • AMX0035 Scientific Rationale in PSP Dr. Jamie Timmons, Head, Global Medical Strategy and Communications, Amylyx • PSP Treatment Landsc |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 23, 2023 |
EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union • Amylyx will seek re-examination of its Conditional Marketing Authorisation Application CAMBRIDGE, Mass. June 23, 2023 — Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced t |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 11, 2023 |
Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results ˗ First quarter 2023 product revenue of $71.4 million; commercial launches of RELYVRIO® in U.S. and ALBRIOZA™ in Canada for the treatment of ALS continue to progress ˗ Regulatory review ongoing in the EU ˗ Expansion of pipeline with first participant dosed in Phase 2 HELIOS study of AMX0035 in Wolfram syndrome and pla |
|
| May 11, 2023 |
Exhibit 10.2 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. AMENDMENT NO. 1, Rev 1 TO THE PRODUCTAGREEMENT BETWEEN PATHEON INC. AND AMYLYXPHARMACEUTICALS, INC. (“Ame |
|
| May 11, 2023 |
Exhibit 10.3 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. AMENDMEMENT NO. 2 TO THE PRODUCT AGREEMENT BETWEEN PATHEONINC. AND AMYLYXPHARMACEUTICALS, INC. (“Amendmen |
|
| May 11, 2023 |
Exhibit 10.4 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. FIRST AMENDMENT TO THE SUPPLY AGREEMENT AMYLYX PHRAMACEUTICAL INC AND CU CHEMIE UETIKONGMBH This First Am |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41199 Amylyx Pharmaceuticals, Inc. |
|
| April 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 3, 2023 |
SC 13D/A 1 d490613dsc13da.htm SC 13D/A CUSIP No. 03237H101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03237H101 (CUSIP Number) Morningside Venture Investments Limited C/O THC Man |
|
| April 3, 2023 |
EX-99.1 CUSIP No. 03237H101 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party. Dated: April 3, |
|
| March 21, 2023 |
EX-10.1 Exhibit 10.1 AMYLYX PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Amylyx Pharmaceuticals, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Compan |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 AMYLYX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or other jurisdiction of incorporation) (Commis |
|
| March 13, 2023 |
List of Subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES Amylyx Pharmaceuticals, Inc. had international subsidiaries shown below as of March 13, 2023. Amylyx Pharmaceuticals, Inc. is not a subsidiary of any other entity. Subsidiary Jurisdiction of Incorporation Amylyx Pharmaceuticals Canada Inc. Canada Amylyx Pharmaceuticals EMEA B.V. Netherlands Amylyx Pharmaceuticals Distribution Ltd. Ireland Amylyx Pharmaceuticals Germany Gm |
|
| March 13, 2023 |
As filed with the Securities and Exchange Commission on March 13, 2023 S-8 As filed with the Securities and Exchange Commission on March 13, 2023 Registration No. |
|
| March 13, 2023 |
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results • Full year product revenue of $22.2 million; commercial launches of RELYVRIO® in U.S. and ALBRIOZA™ in Canada continue to progress • Regulatory review ongoing in the EU • Karen Firestone, CEO and co-founder of Aureus Asset Management and prior fund manager at Fidelity Investments, appointed to the Comp |
|
| March 13, 2023 |
As filed with the Securities and Exchange Commission on March 13, 2023 Table of Contents As filed with the Securities and Exchange Commission on March 13, 2023 Registration No. |
|
| March 13, 2023 |
EX-4.3 Exhibit 4.3 AMYLYX PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Tru |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 13, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Amylyx Pharmaceuticals, Inc. |
|
| March 13, 2023 |
Form of Subordinated Debt Indenture EX-4.4 Exhibit 4.4 AMYLYX PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities a |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41199 Amylyx Pharmace |
|
| March 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Amylyx Pharmaceuticals, Inc. |
|
| March 13, 2023 |
Exhibit 10.18 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Gina Mazzariello, 12 Bridle Path Trail, Newtown, CT. 06470 (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company beginning on February 22, 2022 (the “Effective D |
|
| February 14, 2023 |
SC 13G/A 1 brhc10047886sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 2) Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.0001 par value per s |
|
| February 14, 2023 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03237H 10 1 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| February 14, 2023 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2023 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 AMYLYX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 9, 2023 |
SC 13G 1 tv0259-amylyxpharmaceuticals.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Amylyx Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 03237H101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule |
|
| December 6, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 AMYLYX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 6, 2022 |
Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (?Amendment?) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the ?Company?) and Patrick Yeramian, M.D. (?Executive?) and is effective as of December 1, 2022 (the ?Effective Date?). WHEREAS, the Company and Executive are parties to that certain Employment Agreement, effective January 11, 202 |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41199 Amylyx Pharmaceuticals, Inc. |
|
| November 10, 2022 |
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results ˗ RELYVRIO™ (sodium phenylbutyrate and taurursodiol) approved for the treatment of ALS in adults and now commercially available in the U.S., representing second product launch for Amylyx worldwide ˗ Commercial launch of ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine) in Canada continues to progress ˗ Manageme |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 AMYLYX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 7, 2022 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-267730 Registration No. 333-267766 PROSPECTUS 6,693,750 Shares Common Stock We are offering 6,693,750 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Stock Market, or Nasdaq, under the symbol ?AMLX.? On October 6, 2022, the last reported sale price of our common stock, as reported on Nasdaq, |
|
| October 6, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Amylyx Pharmaceuticals, Inc. |
|
| October 6, 2022 |
As filed with the Securities and Exchange Commission on October 6, 2022. As filed with the Securities and Exchange Commission on October 6, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Amylyx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 46-4600503 (State or other jurisdiction of incorporation or organizati |
|
| October 4, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Amylyx Pharmaceuticals, Inc. |
|
| October 4, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on October 4, 2022. |
|
| October 4, 2022 |
[Remainder of page left intentionally blank] VIA EDGAR October 4, 2022 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| October 4, 2022 |
Form of Underwriting Agreement EX-1.1 Exhibit 1.1 Amylyx Pharmaceuticals, Inc. Common Stock Underwriting Agreement October [●], 2022 Goldman Sachs & Co. LLC BofA Securities, Inc. SVB Securities LLC Evercore Group L.L.C. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282-2198 c/o BofA Securities, Inc. One Bryant |
|
| October 4, 2022 |
[Remainder of page intentionally left blank] Goldman Sachs & Co. LLC 200 West Street New York, NY 10282 BofA Securities, Inc. One Bryant Park New York, NY 10036 SVB Securities LLC 53 State Street, 40th Floor Boston, MA 02109 Evercore Group L.L.C. 55 E. 52nd St. New York, NY 10055 VIA EDGAR October 4, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D. |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.1)* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03237H101 (CUSIP Number) Morningside Venture Investments Limited C/O THC Management Services S.A.M., 2nd Floor, Le Prince De Galles 3-5 |
|
| September 30, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 30, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned, MVIL, LLC is jointly filing the attached Schedule 13D with MORNINGSIDE VENTURE INVESTMENTS LIMITED with respect to the beneficial ownership of securities of Amylyx Pharmaceuticals, Inc. MVIL, LLC By: /s/ Cheng Yee Wing Betty Cheng Yee Wing Betty, Manager |
|
| September 30, 2022 |
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS • RELYVRIO (previously known as AMX0035 in the U.S.) is an oral, fixed-dose combination therapy for the treatment of adults with ALS • RELYVRIO significantly slowed loss of physical function in a randomized, placebo-controlled clinical trial in ALS • Detailed data from the CENTAUR clinical tria |
|
| September 21, 2022 |
AMLX / Amplify YieldShares Oil Hedged MLP Income ETF / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AMYLYX PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03237H101 (CUSIP Number) SEPTEMBER 15, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursua |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.0001 par value per s |
|
| August 24, 2022 |
Table of Contents CONFIDENTIAL TREATMENT REQUESTED BY Amylyx Pharmaceuticals Inc. PURSUANT TO 17 C.F.R. SECTION 200.83 As confidentially submitted to the Securities and Exchange Commission on August 24, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential. Registration No. 333- UNITED STATES |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q lb UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41199 Amylyx Pharmaceuticals, Inc. |
|
| August 11, 2022 |
Exhibit 99.1 Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results - ALBRIOZA? (also known as AMX0035) now commercially available in Canada, representing first product launch for Amylyx - FDA Advisory Committee meeting to review new drug application for AMX0035 for the treatment of ALS scheduled for September 7, 2022; assigned PDUFA action date of September 29, 2022; U.S. commercial |
|
| August 11, 2022 |
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results ? ALBRIOZA? (also known as AMX0035) now commercially available in Canada, representing first product launch for Amylyx ? FDA Advisory Committee meeting to review new drug application for AMX0035 for the treatment of ALS scheduled for September 7, 2022; assigned PDUFA action date of September 29, 2022; U.S. commercial |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 5, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2022 AMYLYX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or other jurisdiction of incorporation) (Commissi |
|
| July 5, 2022 |
Exhibit 99.1 Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022 CAMBRIDGE, Mass. July 5, 2022 ? Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (?Amylyx? or the ?Company?) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that the Agency is planning to reconvene the Periph |
|
| June 21, 2022 |
EX-1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| June 21, 2022 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03237H 10 1 (CUSIP Number) June 8, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| June 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 13, 2022 |
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS • Health Canada decision signifies the first global regulatory approval for Amylyx and the first new therapy for ALS approved in Canada since 2018 • ALBRIOZA (also known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 3, 2022 |
Exhibit 99.1 Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS ? New PDUFA goal date scheduled for September 29, 2022 to allow time to review additional data CAMBRIDGE, Mass. June 3, 2022 ? Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (?Amylyx? or the ?Company?) today announced that the U.S. Food and Drug Administration (FDA) has extended the |
|
| June 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41199 Amylyx Pharmaceuticals, Inc. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 12, 2022 |
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results ? Final stages of commercial launch readiness underway to support the launch of AMX0035 for the treatment of ALS in the U.S. and Canada, if approved ? Data published in Muscle & Nerve further demonstrate significant benefit of AMX0035 on survival in Phase 2 CENTAUR trial participants CAMBRIDGE, Mass. May 12, 2022 - Am |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid |
|
| April 29, 2022 |
DEFA14A 1 d235425ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox |
|
| March 31, 2022 |
Exhibit 21.1 SUBSIDIARIES Amylyx Pharmaceuticals, Inc. had international subsidiaries shown below as of March 31, 2022. Amylyx Pharmaceuticals, Inc.is not a subsidiary of any other entity. Subsidiary Jurisdiction of Incorporation Amylyx Pharmaceuticals Canada Inc. Canada Amylyx Pharmaceuticals EMEA B.V. Netherlands Amylyx Pharmaceuticals Distribution Ltd. Ireland Amylyx Pharmaceuticals Germany Gmb |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 AMYLYX PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41199 46-4600503 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 31, 2022 |
Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results Exhibit 99.1 Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results ? Preparations underway to support potential commercial launch of AMX0035 for the treatment of ALS in the U.S. and Canada, if approved ? FDA assigned PDUFA action date of June 29, 2022 CAMBRIDGE, Mass. March 30, 2022 - Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (?Amylyx? or the ?Company?) today reported financial results |
|
| March 31, 2022 |
Exhibit 4.3 Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Amylyx Pharmaceuticals, Inc. (the ?Company,? ?we,? or ?our?) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Fou |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41199 Amylyx Pharmace |
|
| January 25, 2022 |
Amylyx Pharmaceuticals, Inc. Lock-Up Agreement April 26, 2021 Exhibit 99.3 Amylyx Pharmaceuticals, Inc. Lock-Up Agreement April 26, 2021 Goldman Sachs & Co. LLC SVB Leerink LLC Evercore Group L.L.C. c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 Re: Amylyx Pharmaceuticals, Inc. - Lock |
|
| January 25, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party. MORNINGSIDE VENTURE INVESTMENTS LIMITED By: |
|
| January 25, 2022 |
Amylyx Pharmaceuticals, Inc. Lock-Up Agreement April 26, 2021 Exhibit 99.2 Amylyx Pharmaceuticals, Inc. Lock-Up Agreement April 26, 2021 Goldman Sachs & Co. LLC SVB Leerink LLC Evercore Group L.L.C. c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 Re: Amylyx Pharmaceuticals, Inc. - Lock |
|
| January 25, 2022 |
CUSIP No. 03237H101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03237H101 (CUSIP Number) Morningside Venture Investments Limited C/O THC Management Services S.A.M., 2nd Floor, Le P |
|
| January 21, 2022 |
SC 13G 1 brhc10033006sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Amylyx Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of |
|
| January 12, 2022 |
As filed with the Securities and Exchange Commission on January 12, 2022 As filed with the Securities and Exchange Commission on January 12, 2022 Registration No. |
|
| January 12, 2022 |
2022 Stock Option and Incentive Plan and form of award agreements thereunder. Exhibit 99.2 AMYLYX PHARMACEUTICALS, INC. 2022 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan (as amended from time to time, the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Amylyx Pharma |
|
| January 12, 2022 |
2022 Employee Stock Purchase Plan. Exhibit 99.3 AMYLYX PHARMACEUTICALS, INC. 2022 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Amylyx Pharmaceuticals, Inc. 2022 Employee Stock Purchase Plan (the ?Plan?) is to provide eligible employees of Amylyx Pharmaceuticals, Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, par value $0.0001 per |
|
| January 11, 2022 |
Exhibit 3.2 SECOND AMENDED AND RESTATED BY-LAWS OF AMYLYX PHARMACEUTICALS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors of the Corporation |
|
| January 11, 2022 |
Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMYLYX PHARMACEUTICALS, INC. Amylyx Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Amylyx Pharmaceuticals, Inc. The date of the filing of its original Certificate of Incorporation with the Se |
|
| January 11, 2022 |
8-K 1 d273128d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 AMYLYX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41199 46-4600503 (State or other jurisdictio |
|
| January 10, 2022 |
10,000,000 Shares Common Stock 424B4 1 d155225d424b4.htm 424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-261703 Registration No. 333-262046 10,000,000 Shares Common Stock This is an initial public offering of common stock by Amylyx Pharmaceuticals, Inc. We are offering 10,000,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial pu |
|
| January 6, 2022 |
As filed with the Securities and Exchange Commission on January 6, 2022. As filed with the Securities and Exchange Commission on January 6, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Amylyx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 46-4600503 (State or other jurisdiction of incorporation or organizati |
|
| January 4, 2022 |
FWP 1 d155225dfwp.htm FWP Filed pursuant to Rule 433 Issuer Free Writing Prospectus Registration Statement No. 333-261703 January 4, 2022 Amylyx Pharmaceuticals Submits Marketing Authorization Application (MAA) for AMX0035 for the Treatment of ALS CAMBRIDGE, Mass. January 4, 2022 — Amylyx Pharmaceuticals, Inc. today announced it has submitted a Marketing Authorization Application (MAA) to the Euro |
|
| January 4, 2022 |
[Remainder of page left intentionally blank] VIA EDGAR January 4, 2022 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| January 4, 2022 |
[Remainder of page intentionally left blank] CORRESP 1 filename1.htm Goldman Sachs & Co. LLC 200 West Street New York, NY 10282 SVB Leerink LLC 53 State Street, 40th Floor Boston, MA 02109 Evercore Group L.L.C. 55 E. 52nd St. New York, NY 10055 VIA EDGAR January 4, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford |
|
| January 4, 2022 |
8-A12B 1 d155225d8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Amylyx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4600503 (State of incorporation or organization) (I.R.S. Employer I |
|
| January 3, 2022 |
Exhibit 10.15 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Margaret Olinger, M.B.A. (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933 |
|
| January 3, 2022 |
Form of Underwriting Agreement. Exhibit 1.1 Amylyx Pharmaceuticals, Inc. Common Stock ? Underwriting Agreement [?], 2022 Goldman Sachs & Co. LLC SVB Leerink LLC Evercore Group L.L.C. As representatives (the ?Representatives?) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282-2198 c/o SVB Leerink LLC 53 State Street, 40th Floor Boston, MA 02109 c/o Everco |
|
| January 3, 2022 |
Exhibit 10.12 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Joshua B. Cohen (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amen |
|
| January 3, 2022 |
Exhibit 10.5 AMYLYX PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Amylyx Pharmaceuticals, Inc. (the ?Company?) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its |
|
| January 3, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on January 3, 2022. |
|
| January 3, 2022 |
EX-10.9 14 d155225dex109.htm EX-10.9 Exhibit 10.9 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the 25th day of January, 2021 (the “Effective Date”), by and between JAMES FRATES of 471 Grove Street, Needham, MA 02492 (the “Employee”) and AMYLYX PHARMACEUTICALS, INC., a Delaware corporation duly organized under law and having a usual place of busine |
|
| January 3, 2022 |
Exhibit 10.10 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of the 13th day of May 2019 (the ?Effective Date?), by and between MARGARET OLINGER, MBA of 5134 Cote du Rhone Way, Sarasota, FL 34238 (the ?Employee?) and AMYLYX PHARMACEUTICALS, INC., a Delaware corporation duly organized under law and having a usual place of business at 43 Thorndike Street |
|
| January 3, 2022 |
Exhibit 10.2 AMYLYX PHARMACEUTICALS, INC. 2022 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan (as amended from time to time, the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Amylyx Pharma |
|
| January 3, 2022 |
Exhibit 10.7 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of the 1st day of July, 2015 (the ?Effective Date?), by and between JOSHUA B. COHEN of 373 Columbia Street, Apt. 1, Cambridge, MA 02141 (the ?Employee?) and AMYLYX PHARMACEUTICALS, INC., a Delaware corporation duly organized under law and having a usual place of business 210 Broadway #201, Cam |
|
| January 3, 2022 |
Exhibit 3.4 SECOND AMENDED AND RESTATED BY-LAWS OF AMYLYX PHARMACEUTICALS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors of the Corporation |
|
| January 3, 2022 |
Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PAR VALUE $0.0001 AMYLYX Certificate Number ZQ00000000 Shares * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * AMYLYX PHARMA |
|
| January 3, 2022 |
Exhibit 10.4 AMYLYX PHARMACEUTICALS, INC. EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Executive Cash Incentive Bonus Plan (the ?Incentive Plan?) is intended to promote the achievement of excellent performance and business results, aligning eligible executives of Amylyx Pharmaceuticals, Inc. (the ?Company?) and its subsidiaries goals and interests to those of the Company and its stockholder |
|
| January 3, 2022 |
Exhibit 10.16 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Patrick D. Yeramian, M.D. (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 193 |
|
| January 3, 2022 |
Exhibit 10.14 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and James Frates (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended |
|
| January 3, 2022 |
Exhibit 10.1 AMYLYX PHARMACEUTICALS, INC. 2015 STOCK OPTION AND RESTRICTED STOCK PLAN 1. Purpose. The purpose of this plan (the ?Plan?) is to secure for Amylyx Pharmaceuticals, Inc. (the ?Corporation?) and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Corporation who are expected to contribute to the |
|
| January 3, 2022 |
Exhibit 10.3 AMYLYX PHARMACEUTICALS, INC. 2022 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Amylyx Pharmaceuticals, Inc. 2022 Employee Stock Purchase Plan (the ?Plan?) is to provide eligible employees of Amylyx Pharmaceuticals, Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, par value $0.0001 per |
|
| January 3, 2022 |
Exhibit 10.8 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of the 1st day of August, 2015 (the ?Effective Date?), by and between JUSTIN KLEE of 169 Monsignor O?Brien Highway, Apt. 403, Cambridge, MA 02141 (the ?Employee?) and AMYLYX PHARMACEUTICALS, INC., a Delaware corporation duly organized under law and having a usual place of business 210 Broadway |
|
| January 3, 2022 |
Exhibit 10.13 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Justin Klee (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended |
|
| January 3, 2022 |
Exhibit 3.3 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMYLYX PHARMACEUTICALS, INC. Amylyx Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Amylyx Pharmaceuticals, Inc. The date of the filing of its original Certificate of Incorporation with the Se |
|
| January 3, 2022 |
Exhibit 10.11 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of the 18th day of March 2019 (the ?Effective Date?), by and between PATRICK D. YERAMIAN, M.D. of 1815 SW 22nd Avenue Circle, Boca Raton, FL. 33486 (the ?Employee?) and AMYLYX PHARMACEUTICALS, INC., a Delaware corporation duly organized under law and having a usual place of business at 43 Tho |
|
| December 16, 2021 |
Subsidiaries of the Registrant. EX-21.1 11 d155225dex211.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Amylyx Pharmaceuticals Canada Inc. Canada Amylyx Pharmaceuticals EMEA B.V. Netherlands |
|
| December 16, 2021 |
Exhibit 10.13 AMYLYX PHARMACEUTICALS, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [Officer Name] (“Indemnitee”).1 RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, |
|
| December 16, 2021 |
EX-10.16 10 d155225dex1016.htm EX-10.16 Exhibit 10.16 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. RESEARCH, DEVELOPMENT AND SUPPLY AGREEMENT This agreement (the “ |
|
| December 16, 2021 |
Amended and Restated Bylaws of the Registrant (as currently in effect). Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF AMYLYX PHARMACEUTICALS, INC. Adopted July 1, 2021 AMENDED AND RESTATED BY-LAWS OF AMYLYX PHARMACEUTICALS, INC. ARTICLE I FISCAL YEAR 1 ARTICLE II STOCKHOLDERS 1 Section 1. Annual Meeting 1 Section 2. Special Meetings 1 Section 3. Place of Meetings 1 Section 4. Notices 2 Section 5. Quorum 3 Section 6. Voting and Proxies 3 Section 7. Action at Meeting 4 Se |
|
| December 16, 2021 |
Exhibit 10.15 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. SUPPLY AGREEMENT This Supply Agreement (the ?Agreement?) dated as of October 29, 2019 (the ?Effective Da |
|
| December 16, 2021 |
Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 December 16, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street NE Washington, DC 20549 Attention: Christine Torney Al Pavot Daniel Crawford Joe McCann Re: Amylyx Pharmaceuticals, Inc. Amendment No. 2 to Draft Registration Statement on For |
|
| December 16, 2021 |
Exhibit 10.6 LEASE BY AND BETWEEN BULFINCH SQUARE LIMITED PARTNERSHIP LANDLORD AND AMYLYX PHARMACEUTICALS, INC. TENANT TABLE OF CONTENTS Page Article 1 Reference Data 1 1.1 Introduction and Subjects Referred To 1 1.2 Exhibits 3 Article 2 Premises and Term 3 2.1 Premises 3 2.2 Term 4 2.3 Measurement of the Premises 4 2.4 Early Access 4 Article 3 Commencement and Condition 5 3.1 Commencement Date 5 |
|
| December 16, 2021 |
Exhibit 10.14 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. Master Manufacturing Services Agreement Effective Date: November 12, 2019 PARTIES PATHEON INC. a company |
|
| December 16, 2021 |
Exhibit 4.2 Execution Version AMYLYX PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT July 1, 2021 TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 6 2.2 Company Registration 7 2.3 Underwriting Requirements 8 2.4 Obligations of the Company 8 2.5 Furnish Information 10 2.6 Expenses of Registration 10 2.7 Delay of Registration 10 2 |
|
| December 16, 2021 |
S-1 1 d155225ds1.htm S-1 Table of Contents As filed with the Securities and Exchange Commission on December 16, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Amylyx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 46-4600503 (State or othe |
|
| December 16, 2021 |
Third Amended and Restated Certificate of Incorporation of the Registrant (as currently in effect). Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMYLYX PHARMACEUTICALS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Amylyx Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CER |
|
| December 16, 2021 |
Exhibit 10.12 AMYLYX PHARMACEUTICALS, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of [Date] by and between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and [Director Name] (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, |
|
| November 26, 2021 |
EX-21.1 5 filename5.htm Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Amylyx Pharmaceuticals Canada Inc. Canada Amylyx Pharmaceuticals EMEA B.V. Netherlands |
|
| November 26, 2021 |
Exhibit 10.14 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. Master Manufacturing Services Agreement Effective Date: November 12, 2019 PARTIES PATHEON INC. a company |
|
| November 26, 2021 |
EX-10.15 3 filename3.htm Exhibit 10.15 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SUPPLY AGREEMENT This Supply Agreement (the “Agreement”) dated as of October 29 |
|
| November 26, 2021 |
DRS/A 1 filename1.htm Table of Contents As confidentially submitted to the Securities and Exchange Commission on November 24, 2021. This Amendment No. 2 to the draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20 |
|
| November 26, 2021 |
EX-10.16 4 filename4.htm Exhibit 10.16 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. RESEARCH, DEVELOPMENT AND SUPPLY AGREEMENT This agreement (the “Agreement”) is |
|
| November 24, 2021 |
DRSLTR 1 filename1.htm November 24, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street NE Washington, DC 20549 Attention: Christine Torney Al Pavot Daniel Crawford Joe McCann Re: Amylyx Pharmaceuticals, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted on October 20, 2021 CIK No. 0001658551 Ladies and |
|
| October 20, 2021 |
Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMYLYX PHARMACEUTICALS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Amylyx Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CER |
|
| October 20, 2021 |
AMYLYX PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT July 1, 2021 EX-4.2 4 filename4.htm Exhibit 4.2 Execution Version AMYLYX PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT July 1, 2021 TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 6 2.2 Company Registration 7 2.3 Underwriting Requirements 8 2.4 Obligations of the Company 8 2.5 Furnish Information 10 2.6 Expenses of Registration 10 2.7 Del |
|
| October 20, 2021 |
DRSLTR 1 filename1.htm Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 October 20, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street NE Washington, DC 20549 Attention: David Gessert Joe McCann Christine Torney Al Pavot Re: Amylyx Pharmaceuticals, Inc. Draft Registration Statement on Fo |
|
| October 20, 2021 |
DRS/A 1 filename1.htm Table of Contents As confidentially submitted to the Securities and Exchange Commission on October 20, 2021. This Amendment No. 1 to the draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 205 |
|
| October 20, 2021 |
AMENDED AND RESTATED BY-LAWS AMYLYX PHARMACEUTICALS, INC. Adopted July 1, 2021 EX-3.2 3 filename3.htm Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF AMYLYX PHARMACEUTICALS, INC. Adopted July 1, 2021 AMENDED AND RESTATED BY-LAWS OF AMYLYX PHARMACEUTICALS, INC. ARTICLE I FISCAL YEAR 1 ARTICLE II STOCKHOLDERS 1 Section 1. Annual Meeting 1 Section 2. Special Meetings 1 Section 3. Place of Meetings 1 Section 4. Notices 2 Section 5. Quorum 3 Section 6. Voting and Proxies 3 Section 7. |
|
| April 26, 2021 |
DRS 1 filename1.htm Table of Contents As confidentially submitted to the Securities and Exchange Commission on April 26, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION ST |
